AXIM Biotechnologies, Inc.
AXIM · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 78.3% | 345.3% | -85.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | -$0 | $0 |
| % Margin | -524.1% | 100% | -4,701.4% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $2 | $4 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $2 |
| Operating Expenses | $1 | $3 | $5 | $8 |
| Operating Income | -$2 | -$3 | -$5 | -$8 |
| % Margin | -2,502.3% | -6,961% | -52,425.6% | -13,207.1% |
| Other Income/Exp. Net | -$2 | -$5 | -$2 | -$2 |
| Pre-Tax Income | -$4 | -$8 | -$6 | -$16 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$8 | -$6 | -$17 |
| % Margin | -4,985.2% | -20,395% | -67,120.7% | -27,320.8% |
| EPS | -0.011 | -0.035 | -0.036 | -0.13 |
| % Growth | 68.9% | 1.7% | 72.3% | – |
| EPS Diluted | -0.011 | -0.035 | -0.036 | -0.13 |
| Weighted Avg Shares Out | 319 | 228 | 165 | 132 |
| Weighted Avg Shares Out Dil | 319 | 228 | 165 | 132 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $2 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $2 |
| EBITDA | -$2 | -$6 | -$4 | -$13 |
| % Margin | -3,468.6% | -16,265.7% | -44,398.9% | -21,775.3% |